AstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse

A late-stage clinical trial failed to miss its primary endpoint, U.K.’s laregst drugmaker said Thursday.

Leave a Reply

Your email address will not be published. Required fields are marked *